BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

About this update from Biocardia, Inc.

[{"type":"image","alt":"BioCardia, Inc.","displaySize":"","headline":null,"caption":"BioCardia, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":68,"url":"https://media.zenfs.com/en/globenewswire.com/a5e6da8ba4e1db953fe3f1e134f34300"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qoNytrtYWwAQFfByGKCPTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a5e6da8ba4e1db953fe3f1e134f34300","width":300,"height":68}},"lazy":false},{"type":"text","content":"SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it will participate at the CSI Focus Devices in Heart Failure this week in Frankfurt, Germany. BioCardia’s President and Chief Executive Officer, Peter Altman, PhD, will make an invited presentation entitled, “Intramyocardial Cell Therapy for Ischemic Heart Failure of Reduced Ejection.”","length":511,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:15%;width:15%;min-width:15%;","val":[{"type":"text","content":"Meeting:","length":8,"tagName":"p","attribs":{}}]},{"style":"max-width:85%;width:85%;min-width:85%;","val":[{"type":"text","content":"CSI Focus– Devices therapies in Heart Failure (D-HF)","length":52,"tagName":"p","attribs":{}}]}]},{"val":[{"val":[{"type":"text","content":" ","length":6,"tagName":"p"}]},{"val":[{"type":"text","content":" ","length":6,"tagName":"p"}]}]},{"val":[{"val":[{"type":"text","content":"Day:","length":4,"tagName":"p"}]},{"val":[{"type":"text","content":"Friday, December 5th","length":20,"tagName":"p"}]}]},{"val":[{"val":[{"type":"text","content":" ","length":6,"tagName":"p"}]},{"val":[{"type":"text","content":" ","length":6,"tagName":"p"}]}]},{"val":[{"val":[{"type":"text","content":"Session:","length":8,"tagName":"p"}]},{"val":[{"type":"text","content":"Myocardial structural therapies targeting the ventricles","length":56,"tagName":"p"}]}]},{"val":[{"val":[{"type":"text","content":" ","length":6,"tagName":"p"}]},{"val":[{"type":"text","content":" ","length":6,"tagName":"p"}]}]},{"val":[{"val":[{"type":"text","content":"Time:","length":5,"tagName":"p"}]},{"val":[{"type":"text","content":"10:30 -&nbsp...

More updates from Biocardia, Inc.